ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

https://oncologypro.esmo.org/Meeting-Resour...tatic-pancreatic-cancer-patients-MazoviaGI-1

Pancreatic cancer is the fourth leading cause of cancer death worldwide with a poor prognosis and majority of patients presenting with unresectable disease. Gemcitabine has been considered the primary...

Date: 28 Jun 2017
Presenter: Agnieszka Kolasinska-Cwikła
Resources: Abstract
Topics: Gastrointestinal Cancers, Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...therapy-Outcomes-and-predictors-for-efficacy

The potential benefit of third-line treatment for advanced gastric cancer (AGC) patients is controversial. However, there are patients who keep a good performance status (PS) at second-line chemotherapy...

Date: 28 Jun 2017
Presenter: Mario Uccello
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

https://oncologypro.esmo.org/Meeting-Resour...nhibitor-in-patients-with-cholangiocarcinoma

FGFR2 fusions are found in 10-20% of intrahepatic cholangiocarcinomas (CCAs) and are emerging as targetable drivers in this fatal disease. TAS-120, a novel, covalently bound small-molecule FGFR inhibitor,...

Date: 28 Jun 2017
Presenter: Hendrik-Tobias Arkenau
Resources: Abstract
Topic: Gastrointestinal Cancers

https://oncologypro.esmo.org/Meeting-Resour...er-A-single-centre-experience-from-Bangalore

Palliative chemotherapy in patients with advanced gastric cancer yields better results regarding the improvement of Overall Survival (OS) and the relief of symptoms with minimal mortality and morbidity...

Date: 28 Jun 2017
Presenter: Shashidhara P
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

https://oncologypro.esmo.org/Meeting-Resour...als-at-low-risk-of-screen-relevant-neoplasia

Successful adoption of stool based CRC screening across Europe is straining limited colonoscopy capacity. We have developed a Triage test to reduce unnecessary colonoscopies (no findings or low risk adenomas) in FIT positive individuals.

Date: 28 Jun 2017
Presenter: Marielle Herzog
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...ry-study-for-VEGF-VEGFR-and-SPARC-expression

Patients with liver metastasis from colorectal cancer (CRLM) may achieve prolonged survival after complete resection, although many of these patients will relapse and die of their disease.

Date: 28 Jun 2017
Presenter: Alfonso Cortés Salgado
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...lian-three-or-six-colon-adjuvant-TOSCA-trial

Six months of oxaliplatin-based treatment has been the standard of care as adjuvant therapy for stage III colon cancer and an accepted option for high-risk stage II.

Date: 28 Jun 2017
Presenter: Claudia Mucciarini
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...ork-in-human-metastatic-colorectal-carcinoma

Colorectal cancer (CRC) is a molecularly heterogeneous disease with high mortality rate. Since drug resistance is the limiting factor for successful treatment of patients in metastatic setting, the...

Date: 28 Jun 2017
Presenter: Francesca Maddalena
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...ith-gastric-cancer-after-radical-gastrectomy

The seventh edition of the American Joint Committee on Cancer (AJCC) staging classification for stomach carcinoma has been used worldwide. However, there were still some controversies regarding this staging system.

Date: 28 Jun 2017
Presenter: Jianxian Lin
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

https://oncologypro.esmo.org/Meeting-Resour...ional-prognostic-factor-in-colorectal-cancer

The aim of the presented study was to evaluate prognostic value of suPAR, as an additional inflammatory factor in colorectal cancer patients.

Date: 28 Jun 2017
Presenter: Zofia Stasik
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer